Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors
Clinical Nutrition ESPEN · 2026
DOI: 10.1016/j.clnesp.2026.103288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nutrition ESPEN, 2026. Verfasst von Lai Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chest Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, Sarcopenia, Serum Albumin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND & AIMS: To explore the value of pretreatment myosteatosis and albumin-myosteatosis gauge (AMG) in predicting overall survival (OS) in patients with lung cancer treated with immune checkpoint inhibitors (ICIs). METHODS: This single-center, retrospective study included a total of 119 patients with lung cancer. Myosteatosis was assessed on pretreatment CT at L3 level by mean skeletal muscle density (SMD). AMG was calculated as SMD ∗ serum albumin. The time-dependent receiver operating characteristic curve was used to determine the optimal AMG score cut-off value. The predictive value of myosteatosis and AMG on overall survival was evaluated by the Kaplan-Meier method and Cox proportional hazard models. A nomogram was created based on AMG to predict OS. RESULTS: Patients with low AMG had shorter OS compared with patients with high AMG. (3-year survival rate: low AMG, 20.8% [95%CI: 8.4%-51.9%] versus high AMG, 68.2% [95%CI: 52.4%-88.7%]) No significate difference was observed in patients with and without myosteatosis. (HR = 1.46, 95%CI 0.77-2.76, P = 0.246) In the multivariable analysis, AMG remained a significant predictor of OS. (HR = 3.29, 95% CI 1.51-7.16, p = 0.003) The prediction model for OS based on the AMG was also created with C-index 0.78. A statistically significant but weak positive correlation was observed between myosteatosis and sarcopenia (Phi coefficient = 0.24, p < 0.05). CONCLUSION: AMG was a significant prognostic factor of OS in patients with lung cancer treated with ICIs. A weak correlation between myosteatosis and sarcopenia was observed in patients with lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chest Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Cancer Center, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.
- Department of Nutrition, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China. Electronic address: 13676986549@126.com.
- Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: jinxinrd@alumni.hust.edu.cn.
- Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: 595764747@qq.com.
Zitieren
APA
Wei, L., Tian, M., Han, Q., Wang, W., Jin, X., & Xu, X. (2026). Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors. Clinical Nutrition ESPEN. https://doi.org/10.1016/j.clnesp.2026.103288
Vancouver
Wei L, Tian M, Han Q, Wang W, Jin X, Xu X. Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors. Clinical Nutrition ESPEN. 2026. doi:10.1016/j.clnesp.2026.103288
BibTeX
@article{Wei2026,
author = {Wei, Lai and Tian, Mengxing and Han, Qian and Wang, Wen and Jin, Xin and Xu, Xintian},
title = {Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors},
journal = {Clinical Nutrition ESPEN},
year = {2026},
doi = {10.1016/j.clnesp.2026.103288}
}
EUVIMED